-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $193

Benzinga·04/29/2025 16:59:07
Listen to the news
RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price target from $190 to $193.